Patients were randomized 1:1 to arm 1 (alisertib) or arm 2 (alisertib and fulvestrant). Treatment was assigned using Pocock-Simon dynamic allocation procedure20 (link) with stratification factors: ET resistance (primary vs secondary),21 (link) central laboratory ERα expression (positive vs negative), and prior treatment with CDK 4/6i (yes vs no).
Free full text: Click here